Publications by authors named "Arlene Chan"

Claim this Profile
I
Intermediate endpoints as surrogates for long-term outcomes in breast cancer adjuvant chemotherapy trials.
Andrea Blasco, Sara López-Tarruella, Ander Urruticoechea, Eva Carrasco, Gonzalo Spera, Arlene Chan

Oncologist· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies.
José A García-Saenz, Gonzalo Spera, Marina Pollán, Begoña Bermejo, Manuel Ruiz-Borrego, Arlene Chan

Int J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.
Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux, Arlene Chan

Breast Cancer Res Treat· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.
Peter A Fasching, Dennis Slamon, Zbigniew Nowecki, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Arlene Chan

Clin Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective multi-site study to evaluate the performance and usability of an oral fluid-based HIV self-test in Canada.
Richard A Galli, Darshanand Maraj, Kristin McBain, Jason M Lo Hog Tian, Abbey McFarland, Arlene Chan

BMC Public Health· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer.
Arlene Chan, Jespal Gill, HuiJun Chih, Sarah Christine Elisabeth Wright, Natali Vasilevski

JCO Precis Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109).
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Arlene Chan

Breast Cancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating Two Educational Interventions for Enhancing COVID-19 Knowledge and Attitudes in a Sample American Indian/Alaska Native Population.
Maya Asami Takagi, Simone T Rhodes, Jun Hwan Kim, Maxwell King, Stephanie Soukar, Arlene Chan

Vaccines (Basel)· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer.
Sara M Tolaney, Arlene Chan, Katarina Petrakova, Suzette Delaloge, Mario Campone

J Clin Oncol· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential therapeutic role for pigment epithelium-derived factor in post-menopausal breast cancer bone metastasis.
Naomi Brook, Arun Dharmarajan, Arlene Chan, Crispin R Dass

J Pharm Pharmacol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Dose Dense Chemotherapy in Patients With Obesity: Short-Term Toxicities and Breast Cancer Outcome.
Chris Lomma, HuiJun Chih, Arlene Chan

Clin Breast Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial.
Frankie A Holmes, Beverly Moy, Suzette Delaloge, Stephen K L Chia, Bent Ejlertsen, Arlene Chan

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic role of immune environment in luminal B early breast cancer.
Arlene Chan, Jespal Gill, HuiJun Chih, Delia J Nelson

Cancer Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer.
Arlene Chan, Manuel Ruiz-Borrego, Gavin Marx, A Jo Chien, Hope S Rugo

Breast· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pigment epithelium-derived factor downregulation in oestrogen receptor positive breast cancer bone metastases is associated with menopause.
Naomi Brook, Jespal Gill, HuiJun Chih, Kate Francis, Arun Dharmarajan, Arlene Chan

Mol Cell Endocrinol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer.
Naomi Brook, Jespal Gill, Arun Dharmarajan, Arlene Chan, Crispin R Dass

Int J Mol Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2- Advanced Breast Cancer in the MONALEESA-3 Trial.
Guy Jerusalem, Thomas E Delea, Migule Martin, Michelino De Laurentiis, Arnd Nusch, Arlene Chan, David Chandiwana

Clin Breast Cancer· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor.
On B Chan, John C Su, Anousha Yazdabadi, Arlene Chan

Asia Pac J Clin Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Code of practice needed for samples donated by trial participants.
Robert Coleman, Arlene Chan, Carlos Barrios, David Cameron, Luis Costa

Lancet Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Alberto Ocaña, Jose Ignacio Chacón, Lourdes Calvo, Antonio Antón, Mauro Mansutti, Arlene Chan

Front Oncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J Thaddeus Beck, Arlene Chan

Clin Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03).
Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal J Burstein, Arlene Chan

J Clin Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BreastSurgANZ members recommendations for adjuvant systemic treatment and patient compliance in Australian breast cancer patients.
Arlene Chan, Nicola O'Neil, Chris Lomma, HuiJun Chih, Peter Willsher

ANZ J Surg· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Howard A Burris, Arlene Chan, Aditya Bardia, J Thaddeus Beck, Joohyuk Sohn

Br J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer.
Robert Coleman, Ying Zhou, Danielle Jandial, Benoit Cadieux, Arlene Chan

Adv Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis